Literature DB >> 11434575

Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus.

S C Bae1, H K Koh, D K Chang, M H Kim, J K Park, S Y Kim.   

Abstract

New clinical scales for semiquantitating disease activity in systemic lupus erythematosus (SLE) are widely used in research. They are reliable and valid measures. One of the original scales, the Systemic Lupus Activity Measure (SLAM), has been modified based on experience with it in multi-observer studies and training of individuals in its use. We tested the psychometric properties of the revised SLAM (SLAM-R). SLAM-R was tested on 30 SLE patients, who fulfilled 1997 revised ACR criteria and were selected to represent a range of disease activity. The patients were evaluated independently by two physicians, who studied the instruction booklet and who had never used SLAM-R, on two occasions 2-4 weeks apart. At the first visit, the physician's global assessment of activity using visual analog scale, anti-dsDNA Ab, C3 and C4 were checked for construct validity. The psychometric properties were analyzed with nested analysis of variance and Pearson's correlation coefficient using SAS. All patients were female, the median age was 31 (15-52) y, and the mean score of SLAM-R was 10.5 +/- 5.3 (3-26). Estimates of reliability were 0.78 of inter-rater, 0.61 of inter-visit, 0.76 of physician 1 between visits, and 0.56 of physician 2 between visits. Among subcategories except 'Eye,' the 'Gastrointestinal' category had the highest (0.96) and the 'Neuromotor' category had the lowest inter-rater reliability (0.50). With respect to construct validity, the correlation of SLAM-R scores with the disease activity variables except C4 was high and statistically significant. In conclusion, the SLAM-R is reliable and valid for measuring clinical disease activity in SLE.

Entities:  

Mesh:

Year:  2001        PMID: 11434575     DOI: 10.1191/096120301678646146

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  27 in total

1.  Systemic sclerosis and lupus: points in an interferon-mediated continuum.

Authors:  Shervin Assassi; Maureen D Mayes; Frank C Arnett; Pravitt Gourh; Sandeep K Agarwal; Terry A McNearney; Damien Chaussabel; Nancy Oommen; Michael Fischbach; Kairav R Shah; Julio Charles; Virginia Pascual; John D Reveille; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2010-02

2.  Cytokine balance and behavioral intervention; findings from the Peer Approaches to Lupus Self-Management (PALS) project.

Authors:  Edith M Williams; J Madison Hyer; Ramakrishnan Viswanathan; Trevor D Faith; Leonard Egede; Jim C Oates; Gailen D Marshall
Journal:  Hum Immunol       Date:  2017-07-14       Impact factor: 2.850

3.  A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus.

Authors:  Cynthia Aranow
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

4.  Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort.

Authors:  Deborah M Levy; Christine A Peschken; Lori B Tucker; Gaëlle Chédeville; Adam M Huber; Janet E Pope; Earl D Silverman
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-01       Impact factor: 4.794

5.  Basophil count, a marker for disease activity in systemic lupus erythematosus.

Authors:  Peifen Liang; Ying Tang; Sha Fu; Jun Lv; Bo Liu; Min Feng; Jinggao Li; Deyuan Lai; Xia Wan; Anping Xu
Journal:  Clin Rheumatol       Date:  2014-11-19       Impact factor: 2.980

6.  Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study.

Authors:  Alimohammad Fatemi; Ahmad Raeisi; Zahra Sayedbonakdar; Abbas Smiley
Journal:  Clin Rheumatol       Date:  2017-12-18       Impact factor: 2.980

7.  Cost-effectiveness of a peer mentoring intervention to improve disease self-management practices and self-efficacy among African American women with systemic lupus erythematosus: analysis of the Peer Approaches to Lupus Self-management (PALS) pilot study.

Authors:  E M Williams; C L Dismuke; T D Faith; B L Smalls; E Brown; J C Oates; L E Egede
Journal:  Lupus       Date:  2019-06-05       Impact factor: 2.911

8.  Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside.

Authors:  Chau-Ching Liu; Susan Manzi; Amy H Kao; Jeannine S Navratil; Joseph M Ahearn
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

9.  Determinants of medication non-adherence in Egyptian patients with systemic lupus erythematosus: Sharkia Governorate.

Authors:  Amal B Abdul-Sattar; Sahar A Abou El Magd
Journal:  Rheumatol Int       Date:  2014-11-26       Impact factor: 2.631

Review 10.  How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets.

Authors:  Virginia Pascual; Florence Allantaz; Pinakeen Patel; A Karolina Palucka; Damien Chaussabel; Jacques Banchereau
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.